Relmada Therapeutics (RLMD) Stock Chart & Stock Price History $0.65 -0.02 (-2.78%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$0.67 +0.02 (+3.29%) As of 07/25/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Relmada Therapeutics Stock Price Performance The Relmada Therapeutics (RLMD) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 83.54%, with a year-to-date return of 24.37%. In the past month, the stock has decreased 3.92%, reflecting recent market activity. As of the latest close, Relmada Therapeutics traded at $0.65 with a market cap of $21.46 million and volume of 83,358 shares. Five years ago, the stock traded at $39.01, representing a 98.34% decrease over that period. At the time, it had a market cap of $597.43 million and a volume of 90,044 shares. Receive RLMD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+5.33%1 Month Performance-3.92%3 Month Performance+0.25%Year-To-Date Performance+24.37%1 Year Performance-83.54%5 Year Performance-98.34% RLMD Stock Chart for Saturday, July, 26, 2025 RLMD Chart by TradingView Relmada Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/25/2025$0.67$0.65-2.78%$0.69$0.6483,358 shs$21.46 million07/24/2025$0.72$0.67-7.48%$0.72$0.60457,517 shs$22.08 million07/23/2025$0.63$0.72+14.95%$0.74$0.63871,965 shs$23.87 million07/22/2025$0.61$0.63+1.87%$0.64$0.58254,259 shs$20.76 million07/21/2025$0.58$0.61+6.41%$0.62$0.56248,565 shs$20.38 million07/18/2025$0.60$0.58-3.04%$0.62$0.56214,781 shs$19.15 million07/17/2025$0.61$0.60-1.85%$0.63$0.5994,475 shs$19.75 million07/16/2025$0.63$0.61-4.07%$0.66$0.60259,152 shs$20.12 million07/15/2025$0.63$0.63+0.72%$0.65$0.61109,839 shs$20.98 million07/14/2025$0.61$0.63+2.87%$0.64$0.6169,846 shs$20.83 million Get the Latest News and Ratings for RLMD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/11/2025$0.67$0.61-8.97%$0.68$0.6188,211 shs$20.25 million07/10/2025$0.61$0.67+9.44%$0.69$0.60214,823 shs$22.24 million07/09/2025$0.61$0.61+0.36%$0.64$0.60193,993 shs$20.32 million07/08/2025$0.61$0.61-0.02%$0.68$0.61151,392 shs$20.25 million07/07/2025$0.63$0.61-2.68%$0.64$0.60147,325 shs$20.25 million07/04/2025$0.63$0.63$0.67$0.62297,692 shs$20.81 million07/03/2025$0.60$0.63+4.31%$0.67$0.62297,692 shs$20.81 million07/02/2025$0.62$0.60-2.43%$0.64$0.59185,365 shs$19.95 million07/01/2025$0.60$0.62+2.63%$0.67$0.62183,938 shs$20.45 million06/30/2025$0.61$0.60-1.59%$0.65$0.59194,611 shs$19.92 million06/27/2025$0.67$0.61-9.37%$0.67$0.61277,155 shs$20.25 million06/26/2025$0.54$0.67+24.65%$0.73$0.521.29 million shs$22.34 million06/25/2025$0.59$0.54-8.77%$0.59$0.52647,201 shs$17.92 million Related Companies IGM Biosciences Stock Price Chart Verrica Pharmaceuticals Stock Price Chart Alto Neuroscience Stock Price Chart Metagenomi Stock Price Chart VistaGen Therapeutics Stock Price Chart Adaptimmune Therapeutics Stock Price Chart Oncobiologics Stock Price Chart Surrozen Stock Price Chart Celularity Stock Price Chart Pyxis Oncology Stock Price Chart Receive RLMD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:RLMD) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
